James Michael O'Brien
Net Worth

Last updated:

What is James Michael O'Brien net worth?

The estimated net worth of Mr. James Michael O'Brien is at least $1,681,140 as of 13 Oct 2021. He owns shares worth $8,300 as insider and has received compensation worth at least $1,672,840 in Cognition Therapeutics, Inc..

What is the salary of James Michael O'Brien?

Mr. James Michael O'Brien salary is $418,210 per year as Chief Financial Officer in Cognition Therapeutics, Inc..

How old is James Michael O'Brien?

Mr. James Michael O'Brien is 59 years old, born in 1966.

What stocks does James Michael O'Brien currently own?

As insider, Mr. James Michael O'Brien owns shares in one company:

Company Title Shares Price per share Total value
Cognition Therapeutics, Inc. (CGTX) Chief Financial Officer 5,000 $1.66 $8,300

What does Cognition Therapeutics, Inc. do?

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

James Michael O'Brien insider trading

Cognition Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 5,000 $12 $60,000

Cognition Therapeutics key executives

Cognition Therapeutics, Inc. executives and other stock owners filed with the SEC: